vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and Soho House & Co Inc. (SHCO). Click either name above to swap in a different company.
Soho House & Co Inc. is the larger business by last-quarter revenue ($370.8M vs $207.8M, roughly 1.8× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs -5.0%, a 62.4% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $3.5M).
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
Soho House is an international private members’ club with a focus on the media, arts and fashion industries.
IDYA vs SHCO — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $370.8M |
| Net Profit | $119.2M | $-18.7M |
| Gross Margin | — | — |
| Operating Margin | 52.2% | -1.6% |
| Net Margin | 57.4% | -5.0% |
| Revenue YoY | — | 11.2% |
| Net Profit YoY | 330.1% | -10790.3% |
| EPS (diluted) | $1.33 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $207.8M | $370.8M | ||
| Q2 25 | — | $329.8M | ||
| Q1 25 | — | $282.9M | ||
| Q4 24 | — | $305.6M | ||
| Q3 24 | $0 | $333.4M | ||
| Q2 24 | $0 | $302.9M | ||
| Q1 24 | $0 | $261.9M | ||
| Q4 23 | — | $287.6M |
| Q3 25 | $119.2M | $-18.7M | ||
| Q2 25 | — | $24.9M | ||
| Q1 25 | — | $8.2M | ||
| Q4 24 | — | $-91.7M | ||
| Q3 24 | $-51.8M | $175.0K | ||
| Q2 24 | $-52.8M | $-29.9M | ||
| Q1 24 | $-39.6M | $-41.6M | ||
| Q4 23 | — | $-62.6M |
| Q3 25 | 52.2% | -1.6% | ||
| Q2 25 | — | 18.1% | ||
| Q1 25 | — | 12.3% | ||
| Q4 24 | — | -23.1% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | -4.3% | ||
| Q1 24 | — | -9.3% | ||
| Q4 23 | — | -10.0% |
| Q3 25 | 57.4% | -5.0% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | 2.9% | ||
| Q4 24 | — | -30.0% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | -9.9% | ||
| Q1 24 | — | -15.9% | ||
| Q4 23 | — | -21.8% |
| Q3 25 | $1.33 | $-0.10 | ||
| Q2 25 | — | $0.13 | ||
| Q1 25 | — | $0.04 | ||
| Q4 24 | — | $-0.48 | ||
| Q3 24 | $-0.60 | $0.00 | ||
| Q2 24 | $-0.68 | $-0.15 | ||
| Q1 24 | $-0.53 | $-0.21 | ||
| Q4 23 | — | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $142.5M |
| Total DebtLower is stronger | — | $735.8M |
| Stockholders' EquityBook value | $1.1B | $-351.6M |
| Total Assets | $1.2B | $2.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $786.9M | $142.5M | ||
| Q2 25 | — | $150.3M | ||
| Q1 25 | — | $150.1M | ||
| Q4 24 | — | $152.7M | ||
| Q3 24 | $920.0M | $142.8M | ||
| Q2 24 | $701.7M | $148.5M | ||
| Q1 24 | $698.8M | $139.8M | ||
| Q4 23 | — | $159.2M |
| Q3 25 | — | $735.8M | ||
| Q2 25 | — | $729.8M | ||
| Q1 25 | — | $705.1M | ||
| Q4 24 | — | $691.5M | ||
| Q3 24 | — | $694.8M | ||
| Q2 24 | — | $682.1M | ||
| Q1 24 | — | $671.7M | ||
| Q4 23 | — | $664.9M |
| Q3 25 | $1.1B | $-351.6M | ||
| Q2 25 | — | $-348.6M | ||
| Q1 25 | — | $-340.1M | ||
| Q4 24 | — | $-335.1M | ||
| Q3 24 | $1.2B | $-279.4M | ||
| Q2 24 | $931.7M | $-231.7M | ||
| Q1 24 | $935.3M | $-193.0M | ||
| Q4 23 | — | $-174.9M |
| Q3 25 | $1.2B | $2.7B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | $1.2B | $2.6B | ||
| Q2 24 | $973.7M | $2.6B | ||
| Q1 24 | $961.5M | $2.5B | ||
| Q4 23 | — | $2.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | $34.9M |
| Free Cash FlowOCF − Capex | $142.2M | $3.5M |
| FCF MarginFCF / Revenue | 68.4% | 0.9% |
| Capex IntensityCapex / Revenue | 0.0% | 8.5% |
| Cash ConversionOCF / Net Profit | 1.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | $41.9M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $142.2M | $34.9M | ||
| Q2 25 | — | $41.0M | ||
| Q1 25 | — | $22.8M | ||
| Q4 24 | — | $26.9M | ||
| Q3 24 | $-49.2M | $20.6M | ||
| Q2 24 | $-32.9M | $36.0M | ||
| Q1 24 | $-43.8M | $6.2M | ||
| Q4 23 | — | $18.3M |
| Q3 25 | $142.2M | $3.5M | ||
| Q2 25 | — | $12.4M | ||
| Q1 25 | — | $7.5M | ||
| Q4 24 | — | $18.5M | ||
| Q3 24 | $-49.7M | $10.3M | ||
| Q2 24 | $-33.9M | $10.2M | ||
| Q1 24 | $-45.1M | $-13.5M | ||
| Q4 23 | — | $2.0M |
| Q3 25 | 68.4% | 0.9% | ||
| Q2 25 | — | 3.8% | ||
| Q1 25 | — | 2.7% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 3.4% | ||
| Q1 24 | — | -5.2% | ||
| Q4 23 | — | 0.7% |
| Q3 25 | 0.0% | 8.5% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 5.4% | ||
| Q4 24 | — | 2.7% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 8.5% | ||
| Q1 24 | — | 7.5% | ||
| Q4 23 | — | 5.7% |
| Q3 25 | 1.19× | — | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 2.79× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 117.70× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IDYA
Segment breakdown not available.
SHCO
| Membership | $122.7M | 33% |
| Other | $122.0M | 33% |
| Membership Revenue | $58.5M | 16% |
| Other Revenue | $28.5M | 8% |
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $24.8M | 7% |
| Elimination Of Equity Accounted Revenue | $13.4M | 4% |
| Related Party | $2.0M | 1% |
| Soho House | $1.0M | 0% |
